SOURCE: Astex Therapeutics

January 24, 2006 02:10 ET

Astex grants Cytochrome P450 license to Pfizer

CB4 0WE, UK -- (MARKET WIRE) -- January 24, 2006 --

* Astex continues to strategically leverage its Cytochrome P450 intellectual property through a non-exclusive licensing agreement with Pfizer.

* The action of these enzymes is the cause of adverse drug reactions to many marketed drugs and drug-combination therapies and many failures of novel drugs during their development have been attributed to their interactions with this class of enzymes

* Astex expects that the application of its groundbreaking research, which was published in Nature and Science, will benefit many more companies' drug discovery and development programmes

Contacts
Harren Jhoti, Chief Scientific Officer and Acting CEO
Email: h.jhoti@astex-technology.com
Tel: +44 (0) 1223 226200
Web: www.astex-technology.com

Brunswick Group LLP
Jon Coles / Wendel Verbeek/ Alex Tweed
Tel +44 (0) 207 404 5959
Email: astex@brunswickgroup.com


Copyright © Hugin ASA 2006. All rights reserved.

Contact Information